Neurologist Michio Hirano, MD, provides an overview of thymidine kinase 2 deficiency, discussing its underlying biology, clinical presentation, and natural history before the advent of disease-modifying therapy.
Doxecitine and Doxribtimine Combination Therapy: The First Treatment for Thymidine Kinase 2 Deficiency
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment
2
Phase 3 Biomarker Data Shows Valiltramiprosate Reduces Plasma p-Tau217 in APOE4/4 Carriers
3
The MS "Wearing-Off" Phenomenon: Separating Symptom Burden from Immunological Change
4
Phase 2 APPLAUDS Trial to Test Mivelsiran in Down Syndrome-Associated Alzheimer Disease
5